IMEMR
EMRO
Volume 6, Issue 1 (2025)
3 2025, 6(1): 47-55 |
Back to browse issues page
Ethics code: IR.YUMS.REC.1399.199
History
Received: 2025/01/21 | Accepted: 2025/03/15 | Published: 2025/03/18
Received: 2025/01/21 | Accepted: 2025/03/15 | Published: 2025/03/18
How to cite this article
Gholami D, Abbasi Larki R, Manzuri L, Taheri T, Asfaram A, Sadeghi Mansourkhani H et al . Effect of Oral L-Carnitine and Omega-3 on Lipid Profiles, Sleep Quality, and Quality of Life in Hemodialysis Patients. 3 2025; 6 (1) :47-55
URL: http://jccs.daneshafarand.org/article-8-87165-en.html
URL: http://jccs.daneshafarand.org/article-8-87165-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Authors
D. Gholami1 
, R. Abbasi Larki1 , L. Manzuri2 , T. Taheri3 , A. Asfaram4 , H. Sadeghi Mansourkhani *4 , A. Dehghan5
, R. Abbasi Larki1 , L. Manzuri2 , T. Taheri3 , A. Asfaram4 , H. Sadeghi Mansourkhani *4 , A. Dehghan5
1- Department of Nephrology, Faculty of Medical School, Yasuj University of Medical Sciences, Yasuj, Iran
2- Social Determinants of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
3- Department of Medical-Surgical Nursing, Faculty of Nursing, Yasuj University of Medical Science, Yasuj, Iran
4- Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
5- Student Research Committee, Yasuj University of Medical Sciences, Yasuj, Iran
2- Social Determinants of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
3- Department of Medical-Surgical Nursing, Faculty of Nursing, Yasuj University of Medical Science, Yasuj, Iran
4- Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
5- Student Research Committee, Yasuj University of Medical Sciences, Yasuj, Iran
Abstract (3203 Views)
Aims: This study aimed to evaluate the possible beneficial effects of omega-3 and L-carnitine, as well as their combination, on individuals undergoing hemodialysis.
Materials & Methods: This randomized clinical trial was conducted on 75 hemodialysis patients, divided into three groups (each 25 participants) using a randomized block method. The intervention groups received L-carnitine 250 mg tablets twice a day, one omega-3 capsule, 1000 mg per day, and L-carnitine 250 mg tablets twice a day along with one omega-3 capsule, 1000 mg per day, for three months. Lipid profiles and C-reactive protein levels were measured through laboratory tests before and after the intervention. The quality of life for kidney disease and quality of sleep were assessed using the Kidney Disease Quality of Life Questionnaire and the Pittsburgh Sleep Quality Index, respectively. Data were analyzed using SPSS 20 software.
Findings: The administration of L-carnitine (500 mg per day) did not demonstrate a beneficial effect on high-density lipoprotein, low-density lipoprotein, triglyceride, and C-reactive protein serum levels (p>0.05), but it improved the quality of sleep. Omega-3 supplementation (1000 mg per day) decreased triglyceride and low-density lipoprotein levels, although these reductions were not significant. Additionally, omega-3 treatment significantly improved the quality of life in kidney disease and the quality of sleep in patients undergoing hemodialysis (p<0.05). The coadministration of L-carnitine with omega-3 did not show superior effects compared to omega-3 alone in the evaluated parameters.
Conclusion: Omega-3 supplementation, both alone and in combination with L-carnitine, improves the quality of sleep and life in hemodialysis patients.
Materials & Methods: This randomized clinical trial was conducted on 75 hemodialysis patients, divided into three groups (each 25 participants) using a randomized block method. The intervention groups received L-carnitine 250 mg tablets twice a day, one omega-3 capsule, 1000 mg per day, and L-carnitine 250 mg tablets twice a day along with one omega-3 capsule, 1000 mg per day, for three months. Lipid profiles and C-reactive protein levels were measured through laboratory tests before and after the intervention. The quality of life for kidney disease and quality of sleep were assessed using the Kidney Disease Quality of Life Questionnaire and the Pittsburgh Sleep Quality Index, respectively. Data were analyzed using SPSS 20 software.
Findings: The administration of L-carnitine (500 mg per day) did not demonstrate a beneficial effect on high-density lipoprotein, low-density lipoprotein, triglyceride, and C-reactive protein serum levels (p>0.05), but it improved the quality of sleep. Omega-3 supplementation (1000 mg per day) decreased triglyceride and low-density lipoprotein levels, although these reductions were not significant. Additionally, omega-3 treatment significantly improved the quality of life in kidney disease and the quality of sleep in patients undergoing hemodialysis (p<0.05). The coadministration of L-carnitine with omega-3 did not show superior effects compared to omega-3 alone in the evaluated parameters.
Conclusion: Omega-3 supplementation, both alone and in combination with L-carnitine, improves the quality of sleep and life in hemodialysis patients.
Keywords:
| | Full-Text (HTML) (2825 Views)